Table 4. Effect of spironolactone dosage (combined 2 mg/kg/day and 4 mg/kg/day) on RAS-Fingerprint^™ analytes in 10 healthy purpose-bred Beagle dogs using a cross-over study design at each sampling period at 07:00 (T1) immediately prior to oral dosing of spironolactone.

The sampling periods include two baseline sampling periods at Day 0 (D0) and Day 21 (D21) as well as following two seven-day treatment periods at Day 7 (D7) and Day 28 (D28). Data are presented as median (IQR) in pM/L for AngI, AngII, aldosterone, Ang1-7, Ang1-5, AngIII, AngIV, and PRA-S and as a ratio for ACE-S, AA2, and ALT-S. P value compares overall treatment to baseline at each specific timepoint (D0 vs. D7 and D21 vs. D28).

RAS Fingerprint™ analyte	D0	D7	Fold Difference	P-value	D21	D28	Fold Difference	P-value
AngI(1–10)	95.9 (53.1–164.9)	81.1 (64.0–109.7)	-1.18	0.68	62.7 (38.2–112.5)	136.4 (76.6–167.2)	2.18	0.08
AngII(1–8)	45.3 (33.2–73.6)	47.1 (29.4–59.7)	1.04	0.58	31.9 (22.6–51.9)	70.0 (39.4–81.2)	2.19	0.09
Aldosterone	13.7 (7.0–22.0)	32.4 (13.7–44.7)	2.37	0.28	13.5 (9.5–36.3)	29.4 (10.8–73.6)	2.18	0.25
Ang1-7	22.7 (14.0–44.9)	26.1 (21.0–32.6)	1.15	0.91	18.2 (9.6–28.0)	32.4 (19.4–39.5)	1.78	0.14
Ang1-5	28.3 (18.0–72.2)	41.6 (24.3–54.4)	1.47	0.91	24.2 (16.7–40.2)	52.4 (41.4–62.2)	2.17	0.08
AngIII(2–8)	5.7 (4.3–9.5)	6.9 (4.4–10.4)	1.21	0.97	4.2 (2.5–6.4)	7.5 (4.5–15.0)	1.79	0.22
AngIV(3–8)	10.4 (6.5–16.9)	12.0 (7.1–16.3)	1.15	1	9.6 (4.8–15.8)	15.9 (8.8–27.6)	1.66	0.19
PRA-S	141.2 (84.5–236.9)	124.4 (95.3–166.9)	-1.14	0.74	93.1 (63.2–163.7)	207.3 (113.1–257.7)	2.23	0.06
ACE-S	0.5(0.5–0.6)	0.5 (0.5–0.6)	0	0.97	0.6 (0.5–0.7)	0.5 (0.5–0.7)	-1.2	0.85
AA2	0.3 (0.1–0.6)	0.7 (0.4–0.7)	2.33	0.22	0.4 (0.3–0.6)	0.3 (0.2–1.0)	-1.33	0.68
ALT-S	0.3 (0.3–0.3)	0.3 (0.3–0.4)	0	0.28	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0	0.53